Register to view on-demand recording

Enhancement of Poorly Soluble Drugs
About 40% of approved and 90% of pipeline drugs are poorly soluble, their maximum absorbable dose limited by aqueous solubility. This has led to the adoption of enabled and solubilized dosage forms to deliver these drugs more effectively, including amorphous solid dispersions. Amorphous dispersions are a broadly applicable approach that have been shown to improve API solubility, dissolution rates, and bioavailability of poorly soluble drugs.
This presentation covers:
- Advantages of amorphous drugs
- Development of amorphous solid dispersions using spray drying and hot melt extrusion
- Scale-up of solubilized dosage forms
Presenter

Ruchit Trivedi, PhD
Associate Director of Formulation, BioDuro